The FDA granted priority review to a supplemental biologics license application for Enspryng for myelin oligodendrocyte glycoprotein antibody-associated disease, according to a press release from Roche.
“Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune disease that can attack the optic nerves, brain and spinal cord and cause severe and unpredictable relapses, resulting in accumulating neurological damage, vision loss and disability,” Siân Lennon-Chrimes, PhD, global development leader neuroimmunology at Roche Pharma Development, told Healio.